What’s new
Syapse Deepens Scientific and Technical Expertise with Key Additions to Leadership Team
SAN FRANCISCO, Calif., August 6, 2020 —Syapse®, a real-world evidence company accelerating the delivery of precision medicine through…
ReadSyapse Highlights Real-World Evidence Related to COVID-19 and Cancer at AACR Virtual Meeting
SAN FRANCISCO, Calif., July 22, 2020 — Syapse®, a real-world data company accelerating the delivery of precision medicine through the…
ReadSyapse Expands Real-World Data Network in Asia Through Ajou University Hospital Partnership
SAN FRANCISCO, Calif. and SEOUL, SOUTH KOREA, July 14, 2020 - Syapse®, a real-world data company accelerating the delivery of precisi…
ReadSyapse Announces Research Using Real-World Evidence at ASCO20 Virtual
SAN FRANCISCO – May 29, 2020 – Syapse today announced multiple research abstracts based on real-world data at the ASCO20 Virtual Annual Meet…
ReadSyapse Announces $30M Financing to Advance the Use of Real-World Evidence
SAN FRANCISCO – May 28, 2020 – Syapse, today announced $30 million in new equity funding to accelerate the creation and use of real-world ev…
ReadSyapse, FDA, and Advocate Aurora Health to Present Pneumonitis Safety Data in Plenary Talk at AACR Virtual Meeting
AACR Virtual Annual Meeting Plenary Session April 27, 2020 at 4:00 PM EDT - - - SAN FRANCISCO – April 27, 2020 – Syapse announced that r…
ReadSyapse Appoints Dr. Thomas D. Brown as Chief Medical Officer
SAN FRANCISCO – October 16, 2019 – Syapse today announced the appointment of Thomas D. Brown, MD, MBA as its first Chief Medical Officer. Dr…
ReadSyapse Appoints Fletcher Payne as Chief Financial Officer
SAN FRANCISCO – September 10, 2019 – Syapse, a company accelerating precision medicine through insights derived from its global health syste…
ReadThe real-world evidence project at the FDA adds Syapse to its list of partners in a push past trial boundaries
8/15/19 - The Oncology Center of Excellence is teaming up with San Francisco-based Syapse to expand beyond electronic health records — or EHRs — in building a multi-sourced program involving data drawn from EHRs and registries, as well as molecular data from testing labs.
ReadSyapse Announces Research Collaboration with the FDA Focused on the Regulatory Use of Real-World Evidence
SAN FRANCISCO – August 14, 2019 – Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signe…
ReadSouth Korea’s SNUH extends partnership with Syapse to expand access to precision medicine
8/9/19 - Syapse, a company accelerating precision medicine through insights derived from its global health system network, and Seoul National University Hospital (SNUH) in South Korea announced that they have extended their partnership with a new multi-year agreement. As part of their partnership, SNUH and Syapse will collaboratively work towards building South Koreaâs first real-world data sharing network for leading precision oncology hospitals in the region.
ReadSeoul National University Hospital and Syapse Sign Multi-Year Renewal Agreement to Expand Access to Precision Medicine in South Korea
SAN FRANCISCO and SEOUL, SOUTH KOREA - August 6, 2019 - Syapse, a company accelerating precision medicine through insights derived from its…
ReadSyapse Announces Collaboration with Pfizer in Oncology Precision Medicine Focused on Outcomes Research Using Real-World Evidence
SAN FRANCISCO – July 23, 2019 – Syapse, a company accelerating precision medicine through insights derived from its global health syste…
ReadSyapse, Pfizer enter deal to develop precision medicine in oncology
7/23/19 - San Francisco-based Syapse said Tuesday that it had signed a collaboration deal with New York-based drugmaker Pfizer that will involve using real-world data from Syapseâs network of community health system providers to understand molecular testing and treatment choices. The partnership marks the companyâs third such deal with a major drug company, after it signed similar agreements with Amgen, in May of this year, and Roche, in January 2018.
ReadAmgen taps Syapse to infuse real-world data into its cancer clinical trial designs
5/2/19 - Precision medicine company Syapse has launched a collaboration with its one-time Big Pharma benefactor Amgen, with the goal of mining real-world evidence for insights into cancer drug development. Together, Amgen and Syapse will develop observational research analytics aimed at assessing outcomes in areas of unmet need—starting by identifying existing patients within Syapseâs health network that may be eligible for clinical trials, and then bringing those studies to nearby sites.
ReadAmgen and Syapse Enter Precision Medicine Collaboration in Oncology
THOUSANDS OAKS, Calif - May 2, 2019 - Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicin…
ReadSyapse Oncology Platform Achieves HITRUST CSF Certification
SAN FRANCISCO - April 10, 2019 - Syapse, the leader in powering precision medicine through a global health system network, today announ…
ReadSyapse Presents Data Demonstrating the Effectiveness of its Real-World Data Platform in Harmonizing Molecular Testing Results Across Commercial and Hospital-based Laboratories at Scale
SAN FRANCISCO - April 1, 2019 - Syapse, the leader in powering precision medicine through a global health system network, today announc…
ReadSyapse Hosts Inaugural Precision Medicine Council to Drive Progress in Precision Oncology
San Francisco, Calif. (October 18, 2018) – Syapse, the leading precision medicine company, is convening innovative health systems today in S…
ReadSoftware Veteran James Lim Joins Syapse as Senior Vice President of Product Development
San Francisco, Calif. (July 26, 2018) – Syapse announced today that James Lim has joined the company as Senior Vice President of Product Dev…
ReadSyapse Launches Precision Medicine Council to Advance Health System Adoption of Precision Oncology
San Francisco, Calif. (June 7, 2018) — Syapse, the leading precision medicine company, announced today the formation of the Syapse Precisio…
Read"Syapse Expands Into Asia With Korean Hospital Deal"
1/31/18 - Syapse, a maker of software to support precision oncology care, has entered the Asian market through a partnership with Seoul National University Hospital. A parallel deal with cloud IT company Megazone will allow the company to reach other potential customers in South Korea, Japan, and Vietnam.
Read"Medidata, Syapse partner to enhance oncology clinical trials"
2/12/18 - [Syapse and Medidata] will develop a suite of solutions that will increase cancer patients’ access to clinical trials and also assist trial sponsors in designing eligibility criteria and identifying community health systems as trial sites.
Read"Syapse raises a $30M Series D round to scale its precision medicine program"
11/14/17 - While Syapse does bring fragmented clinical, molecular, treatment, and health outcomes data together, it also puts an emphasis on collaboration with labs and with companies that specialize in clinical trials. The strength of those relationships is evident in the latest funding round.
Read"Community providers will help drive the future of precision medicine"
2/23/18 - Mundane and subtle obstacles like insurance models, legacy processes, and siloed data are defining the on-the-ground reality for precision medicine. All of those are issues that community providers are well-positioned to address.
ReadEvolent Health CEO Frank Williams Joins Syapse Board of Directors
San Francisco, Calif. (March 1, 2018) – Syapse, a leading precision medicine company, announced today that Frank Williams, the co-founder an…
ReadSyapse Expands Philadelphia-area Office
San Francisco, Calif. (February 13, 2018) – Syapse, a leader in precision medicine solutions, has expanded its Philadelphia-area location in…
ReadMedidata and Syapse Announce Partnership to Bring Oncology Clinical Trials into Precision Medicine Era
New York and San Francisco, Calif. (January 31, 2018) – Medidata (NASDAQ: MDSO), the leading global provider of cloud-based technology and d…
ReadSyapse Expands Precision Medicine to Asia through Partnerships with Seoul National University Hospital and Megazone
San Francisco, Calif. and Seoul, Republic of Korea (January 30, 2018) – Syapse, a leading precision medicine company, announced today it is…
ReadSyapse Raises $30 Million to Expand Access to Precision Oncology
San Francisco, Calif. (November 14, 2017) – Syapse, a leader in precision medicine solutions, has raised $30 million in Series D financing,…
Read"Detroit should serve as model for expanding advanced cancer care"
10/26/17 - Just as Henry Ford himself, perhaps one of the greatest innovators in the modern era, changed how cars were manufactured and made available for large populations more than a century ago, we now want Detroit to be known again for innovation — this time for revolutionizing how cancer care is delivered.
Read"Q&A With Syapse CEO Ken Tarkoff"
8/11/17 - Our focus is on improving outcomes for cancer patients. We are, at the highest level, doing what we can to improve outcomes.
Read"Throw out the fax machines: The cancer world needs to modernize molecular test reporting"
7/27/17 - We now know that precision medicine not only works but can lead to better outcomes and quality of life. These benefits will expand exponentially as more providers adopt precision medicine, as they will have a much larger pool of real-world data to inform their insights.
Read"We could do more to fight cancer like McCain’s. The government won’t let us."
7/25/17 - For us to get closer to a treatment for McCain and the thousands of patients that will come after him, physicians and researchers need to be able to easily share data. We need to tear down the wall between the data so that we can radically reduce the lag between insights and treatment.
Read"Syapse president: Precision medicine is the reality of cancer care"
6/27/17 - Precision medicine is providing better outcomes and better quality of life for advanced cancer patients today. That is why precision medicine is not only the future of cancer care, but it is also the present reality of cancer care.
Read"Make no mistake: Cuts to healthcare won’t be superficial "
6/6/2017 - Precision oncology is at a critical inflection point: it’s gaining wide popularity with hospital systems and their oncologists are rushing to make it part of routine cancer care. Now is when we need to be doubling down on precision medicine, accelerating its spread to as many practitioners and patients as we can.
Read"Aurora Health Care launches Oncology Precision Medicine program"
4/24/17 - The clinic will help clinicians provide more care options for patients using new technology not yet available in Wisconsin called Syapse. Syapse is a leading precision medicine software system bringing together previously fragmented clinical, molecular, treatment and outcomes data to support complex clinical decisions.
ReadAurora Cancer Care Teams With Syapse to Launch Precision Medicine Program to Bring Greater Cancer Treatment Options to Patients
Milwaukee, Wis. – Aurora Cancer Care and Syapse, a market leader in precision oncology solutions, have teamed to launch…
Read"Palo Alto startup that fights cancer with software hires CEO"
3/16/17 - Palo Alto-based precision medicine startup Syapse announced Wednesday that it’s hiring former RelayHealth executive Ken Tarkoff as its new CEO.
ReadPrecision Medicine Leader Syapse Announces Ken Tarkoff as New CEO
Palo Alto, Calif. (March 15, 2017) – Syapse, a market leader in precision oncology solutions, announced today that Ken Tarkoff is joining th…
ReadDignity Health and Catholic Health Initiatives Team Up to Launch the Largest Community-Based Precision Medicine Program in the U.S.
SAN FRANCISCO, Calif. and ENGLEWOOD, Colo., September 19, 2016 – Dignity Health and Catholic Health Initiatives (CHI), t…
ReadHenry Ford Health System and Syapse Partner to Launch Cancer Precision Medicine Program
WASHINGTON, D.C., June 29, 2016 - Henry Ford Health System, one of the nation’s leading comprehensive and integrated health system…
ReadCatholic Health Initiatives and Syapse Launch National Cancer Precision Medicine Program
WASHINGTON, D.C.; PALO ALTO, Calif.; ENGLEWOOD, Colo., June 29, 2016 - Catholic Health Initiatives (CHI), the nation’s second-largest nonpro…
ReadOncology Precision Network (OPeN) Announces Data Sharing Commitments at Vice President Biden's Cancer Moonshot Summit
PALO ALTO, Calif.; SALT LAKE CITY, Utah; RENTON, Wash.; STANFORD, Calif., June 29, 2016 - An initiative to end cancer is getting a boost fro…
ReadTAPUR Study Achieves Milestones: Forty-Nine Patients Consent to Participate, Bayer and Merck Sign on as Drug Providers, and Thirty-Seven Sites Are Participating Twelve Weeks Post-Launch
ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) announced today that Bayer and Merck are the most recent companies t…
ReadASCO Kicks off Ground-Breaking Clinical Trial to Learn from Use of Approved Targeted Cancer Therapies Matched to Tumor Genomics
ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) today announced it has begun recruiting patients with advanced cancer for…
ReadWhite House Recognizes Intermountain Healthcare and Syapse for Their Commitment to Precision Medicine
SALT LAKE CITY, Utah and PALO ALTO, Calif., February 26, 2016 – On February 25th, leaders from Intermountain Healthcare, a not-for-profit he…
ReadSyapse Raises $25 Million Series C Round Led by Ascension Ventures to Expand Precision Medicine
PALO ALTO, Calif. and CLAYTON, Mo., January 12, 2016 – Syapse, the leader in precision medicine software, has completed the first close of a…
ReadCaris Life Sciences and Syapse Collaborate to Aggregate Oncology Data that Will Power Precision Medicine and Improve Patient Care
IRVING, Texas and PALO ALTO, Calif., November 18, 2015 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the pro…
ReadA Groundbreaking Global Alliance Forms to Find Effective Response to the Deadliest Human Brain Tumor
A message from Jonathan Hirsch, Syapse Founder & President: “Each year, tens of thousands of people around the world will receive a diagnos…
ReadSyapse Precision Medicine Platform Selected by Leading Oncology Society to Enable Targeted Agent and Profiling Utilization Registry (TAPUR) Study
PALO ALTO, Calif., June 1, 2015 – Syapse, the leading provider of precision medicine software, announced today that its Syapse Precision Med…
ReadASCO Launches First-Ever Clinical Trial: Aims to Learn from Patients with Advanced Cancer Who Lack Standard Treatment Options
Five Leading Pharmaceutical Companies Will Support Innovative Study, Contribute Drugs CHICAGO, Ill., June 1, 2015 – The American Society of…
ReadNew Studies by Intermountain Healthcare’s Intermountain Precision Genomics Reveal that Precision Medicine Improves Survival in Advanced Cancer Patients without Increasing Costs
SALT LAKE CITY, Utah, May 29, 2015 – Two new studies conducted by Intermountain Healthcare’s Intermountain Precision Gen…
Read